Pioneering the Development of Therapeutic Chitin Derivatives
Icelandic Biotechnology Company
Genis is an Icelandic biotechnology company founded in 2005 in the Arctic town of Siglufjordur.
Genis is pioneering the development and application of therapeutic chitin derivatives.
At the heart of the chitin derivatives value proposition is:
The therapeutic ability of chitooligosaccharides (ChOS) to combat multiple inflammatory disorders
The regenerative and osteoinductive properties of our proprietary ChitoBiomer, to be harnessed through development of novel implants promoting bone tissue formation
Effective Therapeutic Solutions
Genis’ goal is to address an unmet need by providing effective therapeutic solutions across a number of inflammatory diseases, as well as developing potent orthobiologic applications based on the osteoinductive and anti-bacterial properties of ChitoBiomer.
Genis Leverages its Science Across 3 Product Platforms
.webp)
Pharmaceutical Development
Novel API development with focus on Rheumatoid arthritis, COPD & Asthma
.webp)
Tissue Regeneration
Orthobiologic medical devices including 3D-printed bone implants and bioactive coating
.webp)
Dietary Supplements
Human and Animal application
Company History
Genis was established to innovate, develop and manufacture novel chitin derivative products obtained by modifying chitin from shrimp shell. Throughout the last two decades, Genis has invested approx. $40M USD in research and development. During that time, the Company has made breakthrough discoveries on chitin biology and adopted a robust strategy of protecting intellectual property through both patents and process know-how.
Our research partners
